Roche gains accelerated approval from the FDA for latest cancer therapy
Considering a recent Phase II trial, the FDA have granted accelerated approval to Roche and Genentech for their bispecfic therapeutic for the treatment of types of lymphoma.
In amongst a flurry of approvals for cancer therapeutics in the last few months, Roche, working with Genentech, adds their treatment, Columvi, to the list.
Columvi, otherwise known as glofitamab, is a bispecific therapy used to treat large B-cell lymphoma, more specifically it is suitable for use in adults with diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that either has relapsed, hasn’t responded to other lines of therapy, or in patients who have had 2 or more treatment options already.
The approval falls under the FDA’s accelerated approval programme, and was granted very quickly, even with a shorter priority review timeline. This brings the treatment up level with Epkinly from AbbVie and Genmab, the other CD20xCD3 bispecific T-cell engager on the market.
The approval comes after showing good consistent results in a Phase II clinical trial, however, unlike Epkinly, the drug from Roche doesn’t address potential treatment of high-grade B-cell lymphoma, even though patients with this presentation made up 7% of the trial subjects. Even so, DLBCL represented the larger cohort and was a main focus of the study.
The treatment is administered currently as an intravenous infusion, which is less accessible than Epkinly, which can be given as a subcutaneous injection, but Roche are working on a formulation that could be administered subcutaneously to elevate the treatment and rival Abbvie/Genmab’s drug.
To Ginna Laport, Genentech’s Global Head of Lymphoma and Chronic Lymphocytic Leukaemia Development, Columvi’s biggest differentiator and distinct advantage is its fixed duration for treatment.
Laport stated that compared to the usual approach of treatment until a cessation of progression, this programme “allows patients for treatment-free interval, [and] it decreases the chance of long-term side effects,” in an interview from the American Society of Clinical Oncology Annual Meeting.
Related News
-
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Women in Pharma: Marketing for the other half in healthcare
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. This instalment highlights not only the importance of ma... -
News CAR-T therapy for renal cell carcinoma gains fast track approval
Joining the strong number of cancer therapies being approved in 2023 is the CAR-T cell therapy from Invectys, the clinical-stage immuno-oncology company. -
News CPHI Podcast Series: The ripple effects of nearshoring in pharma
In the most recent instalment of the CPHI Podcast Series, Digital Editor Lucy Chard is joined by Sandra Sánchez y Oldenhage, President and CEO of PharmAdvice, to discuss nearshoring and reshoring in the pharmaceutical industry, and the subs... -
News Bringing the pharmaceutical supply chain closer to home
The pharmaceutical supply chain has encountered numerous disruptions in the last few years, impacting procurement, manufacturing, packaging, and distribution operations within the pharmaceutical industry. Read about the rise in calls for near/resh... -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed. -
News Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires. -
News President Biden's executive order to increase access to contraception
In the USA, President Joe Biden will be signing an executive order to expand access to contraception.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance